BlackRock’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,680,662
| Closed | -$371M | – | 5697 |
|
|
2025
Q4 | $371M | Buy |
1,680,662
+515,209
| +44% | +$83.3M | 0.01% | 1301 |
|
|
2025
Q3 | $112M | Buy |
1,165,453
+57,785
| +5% | +$3.69M | ﹤0.01% | 2038 |
|
|
2025
Q2 | $54M | Buy |
1,107,668
+1,054,772
| +1,994% | +$25.3M | ﹤0.01% | 2404 |
|
|
2025
Q1 | $1.14M | Sell |
52,896
-2,629
| -5% | -$58.4K | ﹤0.01% | 4158 |
|
|
2024
Q4 | $1.49M | Buy |
55,525
+6,605
| +14% | +$107K | ﹤0.01% | 4118 |
|
|
2024
Q3 | $526K | Buy |
48,920
+408
| +0.8% | +$4.9K | ﹤0.01% | 4311 |
|
|
2024
Q2 | $579K | Buy |
48,512
+12,741
| +36% | +$174K | ﹤0.01% | 4310 |
|
|
2024
Q1 | $658K | Sell |
35,771
-11,137
| -24% | -$160K | ﹤0.01% | 4308 |
|
|
2023
Q4 | $745K | Sell |
46,908
-253
| -0.5% | -$4.06K | ﹤0.01% | 4333 |
|
|
2023
Q3 | $889K | Sell |
47,161
-925
| -2% | -$18.2K | ﹤0.01% | 4280 |
|
|
2023
Q2 | $1.09M | Buy |
48,086
+11,000
| +30% | +$259K | ﹤0.01% | 4271 |
|
|
2023
Q1 | $942K | Buy |
37,086
+30,463
| +460% | +$864K | ﹤0.01% | 4355 |
|
|
2022
Q4 | $100K | Sell |
6,623
-3,207
| -33% | -$38.3K | ﹤0.01% | 5044 |
|
|
2022
Q3 | $124K | Sell |
9,830
-1,829
| -16% | -$25.2K | ﹤0.01% | 5106 |
|
|
2022
Q2 | $114K | Sell |
11,659
-7,370
| -39% | -$91K | ﹤0.01% | 5205 |
|
|
2022
Q1 | $317K | Buy |
19,029
+209
| +1% | +$3.54K | ﹤0.01% | 4995 |
|
|
2021
Q4 | $478K | Buy |
18,820
+2,217
| +13% | +$69K | ﹤0.01% | 4879 |
|
|
2021
Q3 | $743K | Sell |
16,603
-1,917
| -10% | -$72.8K | ﹤0.01% | 4648 |
|
|
2021
Q2 | $747K | Sell |
18,520
-73,133
| -80% | -$3.09M | ﹤0.01% | 4596 |
|
|
2021
Q1 | $4.88M | Buy |
91,653
+2,762
| +3% | +$136K | ﹤0.01% | 3951 |
|
|
2020
Q4 | $3.56M | Buy |
88,891
+3,724
| +4% | +$185K | ﹤0.01% | 3836 |
|
|
2020
Q3 | $4.85M | Buy |
85,167
+5,767
| +7% | +$407K | ﹤0.01% | 3584 |
|
|
2020
Q2 | $5.86M | Buy |
79,400
+73,707
| +1,295% | +$4.78M | ﹤0.01% | 3459 |
|
|
2020
Q1 | $283K | Buy |
5,693
+872
| +18% | +$52.3K | ﹤0.01% | 4164 |
|
|
2019
Q4 | $370K | Sell |
4,821
-6,972
| -59% | -$319K | ﹤0.01% | 4213 |
|
|
2019
Q3 | $470K | Sell |
11,793
-1,355
| -10% | -$45.5K | ﹤0.01% | 4181 |
|
|
2019
Q2 | $441K | Sell |
13,148
-777
| -6% | -$32.3K | ﹤0.01% | 4214 |
|
|
2019
Q1 | $739K | Sell |
13,925
-651
| -4% | -$35.7K | ﹤0.01% | 4003 |
|
|
2018
Q4 | $685K | Buy |
14,576
+279
| +2% | +$19.9K | ﹤0.01% | 4006 |
|
|
2018
Q3 | $1.26M | Sell |
14,297
-1,037
| -7% | -$91.5K | ﹤0.01% | 3897 |
|
|
2018
Q2 | $1.59M | Buy |
15,334
+2,857
| +23% | +$270K | ﹤0.01% | 3817 |
|
|
2018
Q1 | $998K | Buy |
12,477
+9,059
| +265% | +$1.24M | ﹤0.01% | 3883 |
|
|
2017
Q4 | $465K | Buy |
3,418
+81
| +2% | +$12.3K | ﹤0.01% | 4060 |
|
|
2017
Q3 | $541K | Buy |
3,337
+960
| +40% | +$137K | ﹤0.01% | 4050 |
|
|
2017
Q2 | $356K | Sell |
2,377
-26,620
| -92% | -$3.68M | ﹤0.01% | 4106 |
|
|
2017
Q1 | $4.53M | Buy |
28,997
+28,551
| +6,402% | +$5.01M | ﹤0.01% | 3406 |
|
|
2016
Q4 | $93K | Hold |
446
| – | – | ﹤0.01% | 2586 |
|
|
2016
Q3 | $102K | Hold |
446
| – | – | ﹤0.01% | 2572 |
|
|
2016
Q2 | $92K | Buy |
446
+442
| +11,050% | +$107K | ﹤0.01% | 2584 |
|
|
2016
Q1 | $1K | Buy |
+4
| New | +$922 | ﹤0.01% | 3510 |
|
|
2015
Q4 | – | Sell |
-444
| Closed | -$113K | – | 3441 |
|
|
2015
Q3 | $113K | Hold |
444
| – | – | ﹤0.01% | 1703 |
|
|
2015
Q2 | $124K | Buy |
+444
| New | +$137K | ﹤0.01% | 1758 |
|
BlackRock's CDTX Position: Q1 2026 in Review
BlackRock sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 1,680,662 shares — an estimated $371M sold.
BlackRock first reported a position in CDTX in Q2 2015 and held it in 42 quarters. The position peaked at $371M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- BlackRock reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- BlackRock sold 1,680,662 Cidara Therapeutics shares in Q1 2026, an estimated $371M.
- BlackRock first reported a position in Cidara Therapeutics in Q2 2015 and held it in 42 quarters.
- BlackRock's Cidara Therapeutics position peaked at $371M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.